Enhancing Alzheimer's Disease Classification with Transfer Learning: Finetuning a Pre-trained Algorithm.

Curr Med Imaging

School of International Education, Hebei University of Technology, Finland Campus, Lahti-Lappeenranta Cities, Finland.

Published: August 2024

AI Article Synopsis

  • - The study addresses the growing public health issue of Alzheimer's disease (AD) due to an aging population by improving the classification of its stages using the ResNet50V2 deep learning model, which excels in image classification tasks.
  • - A dataset of 6,400 rigorously verified MRI images from diverse sources was used, with the focus on fine-tuning the pre-trained model for multi-class classification of AD by extracting specific features and optimizing input layer sizes for performance.
  • - The model's effectiveness was measured through several metrics, such as accuracy and F1-score, revealing its capacity to differentiate between various stages of AD, supported by visualization tools like confusion matrices to enhance understanding of the results.

Article Abstract

Objective: The increasing longevity of the population has made Alzheimer's disease (AD) a significant public health concern. However, the challenge of accurately distinguishing different disease stages due to limited variability within the same stage and the potential for errors in manual classification highlights the need for more precise approaches to classifying AD stages. In the field of deep learning, the ResNet50V2 model stands as a testament to its exceptional capabilities in image classification tasks.

Materials: The dataset employed in this study was sourced from Kaggle and consisted of 6400 MRI images that were meticulously collected and rigorously verified to assure their precision. The selection of images was conducted with great attention to detail, drawing from a diverse array of sources.

Methods: This study focuses on harnessing the potential of this model for AD classification, a task that relies on extracting disease-specific features. Furthermore, to achieve this, a multi-class classification methodology is employed, using transfer learning and fine-tuning of layers to adapt the pre-trained ResNet50V2 model for AD classification. Notably, the impact of various input layer sizes on model performance is investigated, meticulously striking a balance between capacity and computational efficiency. The optimal fine-tuning strategy is determined by counting layers within convolution blocks and selectively unfreezing and training individual layers after a designated layer index, ensuring consistency and reproducibility. Custom classification layers, dynamic learning rate reduction, and extensive visualization techniques are incorporated.

Results: The model's performance is evaluated using accuracy, AUC, precision, recall, F1-score, and ROC curves. The comprehensive analysis reveals the model's ability to discriminate between AD stages. Visualization through confusion matrices aided in understanding model behavior. The rounded predicted labels enhanced practical utility.

Conclusion: This approach combined empirical research and iterative refinement, resulting in enhanced accuracy and reliability in AD classification. Our model holds promise for real-world applications, achieving an accuracy of 96.18%, showcasing the potential of deep learning in addressing complex medical challenges.

Download full-text PDF

Source
http://dx.doi.org/10.2174/0115734056305633240603061644DOI Listing

Publication Analysis

Top Keywords

alzheimer's disease
8
classification
8
transfer learning
8
deep learning
8
resnet50v2 model
8
model classification
8
model
6
learning
5
enhancing alzheimer's
4
disease classification
4

Similar Publications

Age-related cognitive impairment and dementia pose a significant global health, social, and economic challenge. While Alzheimer's disease (AD) has historically been viewed as the leading cause of dementia, recent evidence reveals the considerable impact of vascular cognitive impairment and dementia (VCID), which now accounts for nearly half of all dementia cases. The Mediterranean diet-characterized by high consumption of fruits, vegetables, whole grains, fish, and olive oil-has been widely recognized for its cardiovascular benefits and may also reduce the risk of cognitive decline and dementia.

View Article and Find Full Text PDF

Microglial polarization and ferroptosis are important pathological features in Alzheimer's disease (AD). Ghrelin, a brain-gut hormone, has potential neuroprotective effects in AD. This study aimed to explore the potential mechanisms by which ghrelin regulates the progression of AD, as well as the crosstalk between microglial polarization and ferroptosis.

View Article and Find Full Text PDF

The long-term health of former athletes with a history of multiple concussions and/or repetitive head impact (RHI) exposure has been of growing interest among the public. The true proportion of dementia cases attributable to neurotrauma and the neurobehavioral profile/sequelae of multiple concussion and RHI exposure among athletes has been difficult to determine. Across three exposure paradigms (i.

View Article and Find Full Text PDF

Background: Edible insects are used for consumption and traditional medicine due to their rich bioactive compounds. This study examined the bioactive compounds and inhibitory effects of crude extracts from Bombyx mori and Omphisa fuscidentalis on α-glucosidase, α-amylase, acetylcholinesterase (AChE), and tyrosinase. Fatty acids, including n-hexadecanoic acid and oleic acid, were identified in the extracts and evaluated for their inhibitory potential against the enzymes in vitro and in silico.

View Article and Find Full Text PDF

From Antipsychotic to Neuroprotective: Computational Repurposing of Fluspirilene as a Potential PDE5 Inhibitor for Alzheimer's Disease.

J Comput Chem

January 2025

Centre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, New South Wales, Australia.

Phosphodiesterase 5 (PDE5) inhibitors have shown great potential in treating Alzheimer's disease by improving memory and cognitive function. In this study, we evaluated fluspirilene, a drug commonly used to treat schizophrenia, as a potential PDE5 inhibitor using computational methods. Molecular docking revealed that fluspirilene binds strongly to PDE5, supported by hydrophobic and aromatic interactions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!